Skip to main content
Back to How We Help Clients


Helping companies capture opportunities across the value chain for generics, branded generics, established products and biosimilars, and forging connections among industry stakeholders.

What we do

We work with all participants in the generics industry, including independent companies, the generics divisions of large corporations, active pharmaceutical ingredient (API) manufacturers, specialty pharmaceutical companies, private equity, wholesalers, pharmacy benefit managers (PBMs), and payors. Our work has covered a wide range of topics, including strategy, operations, marketing, R&D, organization, due diligence, and post-merger management. We offer benchmarking and diagnostic tools in R&D, manufacturing and cost structures.

Forging connections

In keeping with the goals of the practice, we emphasize industry outreach. We convene the Generics CEO Summit for industry leaders, providing an important forum for knowledge sharing and networking. In the past, key discussion topics included capital markets perspectives, biosimilars, quality, and complexity management.

We also attend and present at key external industry conferences, including those organized by the European Generic Medicines Association and the Convention on Pharmaceutical Ingredients (CPhI).

Featured experts

Vikas Bhadoria

Senior Partner, Gurugram

Laura Bremme

Partner, Zurich

Simon Goeller

Partner, Munich

Related insights


Five things to know about biosimilars right now

– In the biosimilars market, companies face declining prices and rising competition. What themes will shape the industry in coming... months, and how can players set themselves apart?

What’s next for pharma in emerging markets?

– Succeeding in emerging markets has been a challenging undertaking for multinational pharma companies, but those that adapt their... end-to-end model for emerging markets could well thrive.